Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Sell
42
TMCI Quote, Financials, Valuation and Earnings
Last price:
$2.91
Seasonality move
:
8.57%
Day range:
$2.76 - $3.00
52-week range:
$2.36 - $10.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.83x
P/B ratio:
2.07x
Volume:
665.4K
Avg. volume:
848.3K
1-year change:
-61.69%
Market cap:
$184.8M
Revenue:
$209.4M
EPS (TTM):
-$0.79
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
|
$52M | -$0.24 | -1.05% | -1650% | $4.87 |
|
CATX
Perspective Therapeutics, Inc.
|
$147K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
INFU
InfuSystem Holdings, Inc.
|
$34.6M | $0.05 | 8.36% | 39.86% | $14.20 |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
|
$2.90 | $4.87 | $184.8M | -- | $0.00 | 0% | 0.83x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8400 | $12.3077 | $211.1M | -- | $0.00 | 0% | 192.56x |
|
INFU
InfuSystem Holdings, Inc.
|
$8.67 | $14.20 | $176.3M | 33.15x | $0.00 | 0% | 1.30x |
|
VNRX
VolitionRX Ltd.
|
$0.33 | $2.20 | $40.9M | -- | $0.00 | 0% | 22.82x |
|
VTAK
Catheter Precision, Inc.
|
$1.98 | -- | $2.4M | 0.40x | $0.00 | 0% | 9.31x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.68 | $1.50 | $95.5M | 66.86x | $0.00 | 0% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
|
44.1% | 1.352 | 16.46% | 2.25x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMCI
Treace Medical Concepts, Inc.
|
$39.7M | -$15.7M | -29.15% | -49.13% | -31.22% | -$11.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Treace Medical Concepts, Inc. vs. Competitors
-
Which has Higher Returns TMCI or CATX?
Perspective Therapeutics, Inc. has a net margin of -32.44% compared to Treace Medical Concepts, Inc.'s net margin of -12425.36%. Treace Medical Concepts, Inc.'s return on equity of -49.13% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About TMCI or CATX?
Treace Medical Concepts, Inc. has a consensus price target of $4.87, signalling upside risk potential of 67.93%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 333.37%. Given that Perspective Therapeutics, Inc. has higher upside potential than Treace Medical Concepts, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Treace Medical Concepts, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMCITreace Medical Concepts, Inc.1 4 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is TMCI or CATX More Risky?
Treace Medical Concepts, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock TMCI or CATX?
Treace Medical Concepts, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMCI or CATX?
Treace Medical Concepts, Inc. quarterly revenues are $50.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Treace Medical Concepts, Inc.'s net income of -$16.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Treace Medical Concepts, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts, Inc. is 0.83x versus 192.56x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMCITreace Medical Concepts, Inc.0.83x -- $50.2M -$16.3M CATXPerspective Therapeutics, Inc.192.56x -- $209K -$26M
-
Which has Higher Returns TMCI or INFU?
InfuSystem Holdings, Inc. has a net margin of -32.44% compared to Treace Medical Concepts, Inc.'s net margin of 6.19%. Treace Medical Concepts, Inc.'s return on equity of -49.13% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.
Company Gross Margin Earnings Per Share Invested Capital TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M -
What do Analysts Say About TMCI or INFU?
Treace Medical Concepts, Inc. has a consensus price target of $4.87, signalling upside risk potential of 67.93%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 63.78%. Given that Treace Medical Concepts, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Treace Medical Concepts, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMCITreace Medical Concepts, Inc.1 4 0 INFUInfuSystem Holdings, Inc.5 0 0 -
Is TMCI or INFU More Risky?
Treace Medical Concepts, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.
-
Which is a Better Dividend Stock TMCI or INFU?
Treace Medical Concepts, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMCI or INFU?
Treace Medical Concepts, Inc. quarterly revenues are $50.2M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Treace Medical Concepts, Inc.'s net income of -$16.3M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Treace Medical Concepts, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts, Inc. is 0.83x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMCITreace Medical Concepts, Inc.0.83x -- $50.2M -$16.3M INFUInfuSystem Holdings, Inc.1.30x 33.15x $36.5M $2.3M
-
Which has Higher Returns TMCI or VNRX?
VolitionRX Ltd. has a net margin of -32.44% compared to Treace Medical Concepts, Inc.'s net margin of -862.39%. Treace Medical Concepts, Inc.'s return on equity of -49.13% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About TMCI or VNRX?
Treace Medical Concepts, Inc. has a consensus price target of $4.87, signalling upside risk potential of 67.93%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 560.66%. Given that VolitionRX Ltd. has higher upside potential than Treace Medical Concepts, Inc., analysts believe VolitionRX Ltd. is more attractive than Treace Medical Concepts, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMCITreace Medical Concepts, Inc.1 4 0 VNRXVolitionRX Ltd.4 2 0 -
Is TMCI or VNRX More Risky?
Treace Medical Concepts, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock TMCI or VNRX?
Treace Medical Concepts, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMCI or VNRX?
Treace Medical Concepts, Inc. quarterly revenues are $50.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Treace Medical Concepts, Inc.'s net income of -$16.3M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Treace Medical Concepts, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts, Inc. is 0.83x versus 22.82x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMCITreace Medical Concepts, Inc.0.83x -- $50.2M -$16.3M VNRXVolitionRX Ltd.22.82x -- $627.3K -$5.4M
-
Which has Higher Returns TMCI or VTAK?
Catheter Precision, Inc. has a net margin of -32.44% compared to Treace Medical Concepts, Inc.'s net margin of -1037.17%. Treace Medical Concepts, Inc.'s return on equity of -49.13% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About TMCI or VTAK?
Treace Medical Concepts, Inc. has a consensus price target of $4.87, signalling upside risk potential of 67.93%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1819.25%. Given that Catheter Precision, Inc. has higher upside potential than Treace Medical Concepts, Inc., analysts believe Catheter Precision, Inc. is more attractive than Treace Medical Concepts, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMCITreace Medical Concepts, Inc.1 4 0 VTAKCatheter Precision, Inc.0 0 0 -
Is TMCI or VTAK More Risky?
Treace Medical Concepts, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock TMCI or VTAK?
Treace Medical Concepts, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMCI or VTAK?
Treace Medical Concepts, Inc. quarterly revenues are $50.2M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. Treace Medical Concepts, Inc.'s net income of -$16.3M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, Treace Medical Concepts, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts, Inc. is 0.83x versus 9.31x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMCITreace Medical Concepts, Inc.0.83x -- $50.2M -$16.3M VTAKCatheter Precision, Inc.9.31x 0.40x $226K -$2.3M
-
Which has Higher Returns TMCI or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -32.44% compared to Treace Medical Concepts, Inc.'s net margin of 3.93%. Treace Medical Concepts, Inc.'s return on equity of -49.13% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital TMCITreace Medical Concepts, Inc.79.07% -$0.26 $159.6M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About TMCI or XTNT?
Treace Medical Concepts, Inc. has a consensus price target of $4.87, signalling upside risk potential of 67.93%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 119.94%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Treace Medical Concepts, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Treace Medical Concepts, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TMCITreace Medical Concepts, Inc.1 4 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is TMCI or XTNT More Risky?
Treace Medical Concepts, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock TMCI or XTNT?
Treace Medical Concepts, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMCI or XTNT?
Treace Medical Concepts, Inc. quarterly revenues are $50.2M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Treace Medical Concepts, Inc.'s net income of -$16.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Treace Medical Concepts, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 66.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts, Inc. is 0.83x versus 0.74x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMCITreace Medical Concepts, Inc.0.83x -- $50.2M -$16.3M XTNTXtant Medical Holdings, Inc.0.74x 66.86x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
